NTN1 and COVID-19: Furthermore, UNAGI highlighted potential IPF therapeutic pathways, including Netrin-1 signalling and ROBO receptors, and potential drugs such as nifedipine as an anti-fibrotic, as well as identified repurposed drugs for COVID-19, such as aloxistatin and didanosine, demonstrating its broad potential in biomedical research.